Suscribirse

The novel relationship between polycystic ovary syndrome and temporomandibular joint disorders - 22/11/20

Doi : 10.1016/j.jormas.2020.10.008 
Hasmet Yazici a, , Mine Islimye Taskin b , Gurhan Guney b , Adnan Adil Hismiogullari c , Erhan Arslan a , Kamil Gokce Tulaci a
a Balıkesir University Medical Faculty, Department of Otolaryngology–Head and Neck Surgery, Balıkesir, Turkey 
b Balıkesir University Medical Faculty, Department of Reproductive Endocrinology and Infertility, Balıkesir, Turkey 
c Balıkesir University Medical Faculty, Department of Biochemistry, Balıkesir, Turkey 

Corresponding author at: Balıkesir University Medical Faculty, Department of Otolaryngology–Head and Neck Surgery, 10145, Çağış Kampüsü, Balıkesir, Turkey.Balıkesir University Medical FacultyDepartment of Otolaryngology–Head and Neck SurgeryÇağış KampüsüBalıkesir10145Turkey
En prensa. Pruebas corregidas por el autor. Disponible en línea desde el Sunday 22 November 2020
This article has been published in an issue click here to access

Abstract

Introduction

Studies investigating the relationship between sex hormones, inflammatory mediators and joint disorders have reported that sex hormones affect the pathogenesis of joint disorders. We aimed to investigate temporomandibular joint disorder (TJD) in polycystic ovary syndrome (PCOS) and the possible role of systemic mediators and sex hormones in TJD pathogenesis.

Material and methods

PCOS patients (n = 45) and controls (n = 30) aged 20–40 years, were enrolled in this case-control study. TJD diagnosis was performed by the specialist and blood samples were tested in the early follicular phase and on the 21 st (midluteal) day to investigate the levels of estrogen, progesterone, matrix metalloproteinase (MMP) 1-8-9, interleukin (IL)-1ß and Tumor necrosis factor (TNF)-α.

Results

TJD incidence was significantly higher in PCOS than the control group (51.1% and 6.9% respectively, p < 0.01). Midluteal progesterone (p < 0.01) was lower in PCOS group than the controls (p < 0.01). TNF-α (p < 0.01), MMP 1 (p < 0.01) and MMP 8 (p = 0.02) levels were found significantly higher in PCOS than the control group. Further, Progesterone levels were found significantly lower in TJD (+) PCOS patients than TJD (-) PCOS patients. However, significant difference was not found between the PCOS TJD (+) and PCOS TJD (-) patients for estrogen, MMP 1, MMP 8, MMP 9, TNF-α and IL-1ß.

Conclusions

TJD frequency was found significantly increased in PCOS patients. Related with this, TJD co-occurrence should be kept in mind in the diagnosing and treatment process of PCOS due to hormonal alteration.

El texto completo de este artículo está disponible en PDF.

Keywords : Polycystic ovary syndrome, Temporomandibular joint disorders, Matrix metalloproteinases, Estrogen, Progesterone


Esquema


© 2020  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.